Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
NHL
MCID: LYM143
MIFTS: 74

Lymphoma, Non-Hodgkin, Familial (NHL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lymphoma, Non-Hodgkin, Familial

About this section

MalaCards integrated aliases for Lymphoma, Non-Hodgkin, Familial:

Name: Lymphoma, Non-Hodgkin, Familial 58 39 41
Non-Hodgkin Lymphoma 58 39 12 77 30 6 15
Lymphoma, Non-Hodgkin 58 13 74
Nhl 58 76
Lymphoma, Non-Hodgkin, Somatic 58
Lymphoma, Follicular, Somatic 58
Familial Non-Hodgkin Lymphoma 76
Non-Hodgkin Lymphoma; Nhl 58
Lymphoma Non-Hodgkins 56
Non-Hodgkins Lymphoma 17

Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:0060060
OMIM 58 605027
ICD10 34 C85.7
MedGen 43 C0024305
UMLS 74 C0024305
Sources

Summaries for Lymphoma, Non-Hodgkin, Familial

About this section
UniProtKB/Swiss-Prot : 76 Familial non-Hodgkin lymphoma: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.

MalaCards based summary : Lymphoma, Non-Hodgkin, Familial, also known as non-hodgkin lymphoma, is related to anaplastic large cell lymphoma and diffuse large b-cell lymphoma. An important gene associated with Lymphoma, Non-Hodgkin, Familial is CASP10 (Caspase 10), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs rituximab and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are lymphoma and Reduced mammosphere formation

Disease Ontology : 12 A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma.

Wikipedia : 77 Non-Hodgkin lymphoma (NHL) is a group of blood cancers that includes all types of lymphoma except... more...

Description from OMIM: 605027
Sources

Related Diseases for Lymphoma, Non-Hodgkin, Familial

About this section

Diseases related to Lymphoma, Non-Hodgkin, Familial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 490)
# Related Disease Score Top Affiliating Genes
1 anaplastic large cell lymphoma 34.0 ALK NPM1 PAX5 PTPRC
2 diffuse large b-cell lymphoma 33.8 BCL10 BCL6 CD5 IRF4 MYC TP53
3 b-cell lymphomas 33.8 BCL10 BCL6 CCND1 CD5 IRF4 MS4A1
4 lymphoma, mucosa-associated lymphoid type 33.8 BCL10 BCL6 CCND1 CD5 IRF4
5 follicular lymphoma 33.6 BCL10 BCL6 CCND1 IRF4 MYC
6 richter's syndrome 33.6 CD5 IRF4 MYC TP53
7 composite lymphoma 33.2 BCL6 CD5 PAX5
8 reticulosarcoma 33.1 ALK BCL6 NPM1 PAX5 PTPRC
9 plasmablastic lymphoma 33.1 BCL6 MS4A1 MYC PTPRC
10 follicular lymphoma 1 33.0 BCL10 BCL6
11 lymphosarcoma 32.6 BCL6 CD5 PTPRC
12 lymphoma 32.5 ALK BCL10 BCL6 CASP10 CCND1 MYC
13 lymphoma, hodgkin, classic 32.5 ALK BCL6 CD5 PAX5 PTPRC
14 leukemia, chronic lymphocytic 32.2 BCL10 BCL6 BRAF CCND1 CD5 MS4A1
15 leukemia, chronic lymphocytic 2 32.2 BRAF NRAS TP53
16 myeloma, multiple 32.0 BRAF CCND1 IRF4 MYC NRAS PTPRC
17 primary mediastinal large b-cell lymphoma 31.9 BCL6 IRF4 MYC
18 leukemia, acute myeloid 31.6 MYC NPM1 NRAS PTPRC TP53
19 hodgkin's lymphoma, lymphocytic-histiocytic predominance 31.6 BCL6 PTPRC
20 acquired immunodeficiency syndrome 31.6 BCL6 MYC TP53
21 marginal zone b-cell lymphoma 31.4 BCL10 BCL6 CCND1 CD5 IRF4
22 adenocarcinoma 31.4 ALK BRAF CCND1 MYC PIK3CA TP53
23 hairy cell leukemia 31.4 BRAF CCND1 CD5
24 lymphocytic leukemia 31.3 CD5 MYC PAX5 TP53
25 mantle cell lymphoma 31.3 BCL6 CCND1 CD5 MYC PAX5 PTPRC
26 thyroid cancer 31.3 BRAF CCND1 MYC NRAS PIK3CA TP53
27 burkitt lymphoma 31.2 BCL6 MS4A1 MYC PAX5
28 neuroblastoma 31.2 ALK MYC NRAS PIK3CA TP53
29 lymphoproliferative syndrome 31.2 CASP10 NRAS PRF1
30 pancreas adenocarcinoma 31.2 CCND1 MYC PIK3CA TP53
31 skin melanoma 31.1 BRAF NRAS TP53
32 lymphoblastic lymphoma 31.1 BCL6 CD5 PTPRC
33 histiocytoma 31.1 ALK PTPRC TP53
34 gastric lymphoma 31.0 BCL10 BCL6 TP53
35 cll/sll 31.0 CCND1 CD5 PAX5 TP53
36 brain cancer 31.0 ALK BRAF MYC NRAS PIK3CA TP53
37 lung cancer susceptibility 3 31.0 ALK BRAF CCND1 NRAS PIK3CA TP53
38 glioblastoma 31.0 ALK BRAF CCND1 MYC NRAS PIK3CA
39 autoimmune lymphoproliferative syndrome 31.0 CASP10 NRAS PRF1 PTPRC
40 autoimmune lymphoproliferative syndrome, type v 30.9 ALK BCL6 CD5
41 small cell cancer of the lung 30.9 MYC PAX5 PIK3CA TP53
42 splenic marginal zone lymphoma 30.9 BCL6 CD5 PAX5
43 cholangiocarcinoma 30.9 BRAF CCND1 PIK3CA TP53
44 breast ductal carcinoma 30.8 CCND1 RAD54L TP53
45 prolymphocytic leukemia 30.8 CCND1 CD5 MYC
46 breast lymphoma 30.8 BCL6 CD5
47 peripheral t-cell lymphoma 30.8 ALK BCL6 CD5 MS4A1
48 plasma cell leukemia 30.8 CCND1 IRF4
49 primary effusion lymphoma 30.8 BCL6 IRF4 MYC
50 nodular lymphocyte predominant hodgkin lymphoma 30.8 BCL6 PAX5

Graphical network of the top 20 diseases related to Lymphoma, Non-Hodgkin, Familial:



Diseases related to Lymphoma, Non-Hodgkin, Familial
Sources

Symptoms & Phenotypes for Lymphoma, Non-Hodgkin, Familial

About this section

Human phenotypes related to Lymphoma, Non-Hodgkin, Familial:

33
# Description HPO Frequency HPO Source Accession
1 lymphoma 33 HP:0002665

Clinical features from OMIM:

605027

GenomeRNAi Phenotypes related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.5 BCL6 BRAF CCND1 CD5 MYC NRAS
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 BCL10 RAD54B RAD54L TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 BCL10 BRAF CCND1 MYC RAD54B RAD54L

MGI Mouse Phenotypes related to Lymphoma, Non-Hodgkin, Familial:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.42 BCL10 BCL6 BRAF CCND1 IRF4 MYC
2 hematopoietic system MP:0005397 10.41 BCL10 BCL6 BRAF CCND1 CD5 IRF4
3 immune system MP:0005387 10.38 BCL10 BCL6 BRAF CCND1 CD5 IRF4
4 growth/size/body region MP:0005378 10.34 ALK BCL6 BRAF CCND1 IRF4 MYC
5 homeostasis/metabolism MP:0005376 10.31 ALK BCL6 BRAF CCND1 IRF4 MYC
6 endocrine/exocrine gland MP:0005379 10.28 ALK BCL10 BCL6 BRAF CCND1 MYC
7 mortality/aging MP:0010768 10.28 ALK BCL10 BCL6 BRAF CCND1 MYC
8 integument MP:0010771 10.16 ALK BRAF CCND1 CD5 MYC NPM1
9 neoplasm MP:0002006 10.15 ALK BRAF CCND1 IRF4 MYC NPM1
10 nervous system MP:0003631 10.1 ALK BCL10 BRAF CCND1 CD5 MYC
11 liver/biliary system MP:0005370 10.03 BCL6 BRAF MYC NPM1 NRAS PRF1
12 normal MP:0002873 9.85 BCL6 BRAF CCND1 CD5 MYC NRAS
13 no phenotypic analysis MP:0003012 9.8 BCL6 CD5 MYC NRAS PIK3CA PTPRC
14 pigmentation MP:0001186 9.35 ALK BRAF MYC NRAS TP53
15 skeleton MP:0005390 9.28 ALK BRAF CCND1 MYC NRAS PAX5
Sources

Drugs & Therapeutics for Lymphoma, Non-Hodgkin, Familial

About this section

Drugs for Lymphoma, Non-Hodgkin, Familial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 721)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
4
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
7
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3778-73-2 3690
8
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
9
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
10
Epirubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 56420-45-2 41867
11
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 6857599 5310940 9887054 43805
12
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
13
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
14
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
15
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
16
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
17
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
18
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
19
Entecavir Approved, Investigational Phase 4,Phase 2,Not Applicable 142217-69-4 153941
20
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
21
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 24356-66-9 21704 32326
22
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
23
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59917-39-4, 53643-48-4 40839
24
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
25
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
26
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
27
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
28
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 148-82-3 460612 4053
29
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
30
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
31
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177 70789204
32
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
33
Angiotensin II Approved, Investigational Phase 4,Phase 1 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
34
Prilocaine Approved Phase 4 721-50-6 4906
35
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
36
Nitric Oxide Approved Phase 4 10102-43-9 145068
37
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
38
Mechlorethamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-75-2 4033
39
Sofosbuvir Approved Phase 4,Phase 2 1190307-88-0 45375808
40
Ledipasvir Approved Phase 4,Phase 2 1256388-51-8 67505836
41
Ribavirin Approved Phase 4,Phase 3,Early Phase 1 36791-04-5 37542
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
43
Tenofovir Experimental, Investigational Phase 4,Phase 3,Phase 1,Phase 2 147127-20-6 464205
44
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
45
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
46
Pirarubicin Investigational Phase 4 72496-41-4
47 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2426)
# Name Status NCT ID Phase Drugs
1 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Unknown status NCT02585947 Phase 4 Tenofovir
2 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
3 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
4 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
5 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
6 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
7 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
8 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
9 Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
10 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
11 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4 rituximab
12 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
13 Prevention of CHOP-induced Chronic Cardiotoxicity Completed NCT00162955 Phase 4 Valsartan
14 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
15 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
16 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
17 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4 Epoetin Beta
18 Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture Completed NCT00808171 Phase 4 Livopan;Livopan;EMLA
19 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
20 Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study Terminated NCT02717949 Phase 4 sofosbuvir/ledipasvir;sofosbuvir;Ribavirin
21 Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients. Withdrawn NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
22 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
23 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
24 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
25 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
26 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
27 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
28 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
29 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
30 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
31 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
32 Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
33 Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00129090 Phase 3 R-CHOEP 14 with 12x Rituximab
34 Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma Unknown status NCT00463463 Phase 3 90Yttrium Ibritumomab Tiuxetan (Zevalin)
35 A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma Unknown status NCT00078598 Phase 3 Rituximab or Iodine I 131 Tositumomab Therapy
36 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
37 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
38 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Unknown status NCT00003423 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;prednisolone;thioguanine;vincristine sulfate
39 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
40 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
41 Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
42 Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma Unknown status NCT00017290 Phase 3 cyclophosphamide;prednisone;vincristine sulfate
43 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Unknown status NCT00003650 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
44 Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
45 Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Unknown status NCT00022685 Phase 3
46 Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma Unknown status NCT01570049 Phase 3 Bendamustine
47 Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
48 Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma Unknown status NCT00091676 Phase 3
49 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma Unknown status NCT00006250 Phase 3 chlorambucil;dexamethasone;fludarabine phosphate;mitoxantrone hydrochloride
50 High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003578 Phase 3 CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate

Search NIH Clinical Center for Lymphoma, Non-Hodgkin, Familial

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Non-Hodgkin, Familial cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Lymphoma, Non-Hodgkin, Familial:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Hematopoietic stem cells for treatment of non-Hodgkin's lymphoma
StemEx�, umbilical cord blood stem/progenitor cells for hematological diseases
Embryonic/Adult Cultured Cells Related to Lymphoma, Non-Hodgkin, Familial:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells
Peripheral blood-derived hematopoietic stem cells PMIDs: 21831743
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724
Sources

Genetic Tests for Lymphoma, Non-Hodgkin, Familial

About this section

Genetic tests related to Lymphoma, Non-Hodgkin, Familial:

# Genetic test Affiliating Genes
1 Non-Hodgkin Lymphoma 30 BCL10 CASP10 PRF1 RAD54B RAD54L
Sources

Anatomical Context for Lymphoma, Non-Hodgkin, Familial

About this section

MalaCards organs/tissues related to Lymphoma, Non-Hodgkin, Familial:

42
B Cells, T Cells, Bone, Bone Marrow, Breast, Nk Cells, Lymph Node
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Non-Hodgkin, Familial:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
Sources

Publications for Lymphoma, Non-Hodgkin, Familial

About this section

Articles related to Lymphoma, Non-Hodgkin, Familial:

(show top 50) (show all 3099)
# Title Authors Year
1
Non-Hodgkin lymphoma presenting as acute pancreatitis: A rare occurrence. ( 30656020 )
2019
2
Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma. ( 30790227 )
2019
3
Shared Medical and Environmental Risk Factors in Dry Eye Syndrome, Sjogren's Syndrome, and B-Cell Non-Hodgkin Lymphoma: A Case-Control Study. ( 30805374 )
2019
4
The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma. ( 30693983 )
2019
5
Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States. ( 30848975 )
2019
6
Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma. ( 30701466 )
2019
7
Hepatitis C virus infection is a risk factor for non-Hodgkin lymphoma: A MOOSE-compliant meta-analysis. ( 30882645 )
2019
8
High Prevalence of Hepatitis C Virus among B-Cell Non Hodgkin Lymphoma Patients in Mansoura Region (Egypt), ANRS 12263 Study. ( 30671217 )
2019
9
Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma. ( 30843894 )
2019
10
Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. ( 30859374 )
2019
11
Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma. ( 30906531 )
2019
12
B-cell non-Hodgkin lymphoma discovery after observation of a platelet satellitism around atypical lymphocytes. ( 30907360 )
2019
13
Cardiovascular mortality among patients with non-Hodgkin lymphoma: differences according to lymphoma subtype. ( 30916804 )
2019
14
Current Real-Life Results and Future Options of Gemcitabine-Based Salvage Therapy for Relapsed or Refractory Non-Hodgkin Lymphoma. ( 30836362 )
2019
15
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. ( 30850381 )
2019
16
Concomitant occurrence of primary renal non-Hodgkin lymphoma and a colon cancer: A rare case report. ( 30855498 )
2019
17
Global patterns and trends in the incidence of non-Hodgkin lymphoma. ( 30895415 )
2019
18
Early evaluation of tumor response to 90Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT? ( 30899979 )
2019
19
Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study. ( 30901086 )
2019
20
CAR T-Cell Therapy in Non-Hodgkin Lymphoma Patients. ( 30784033 )
2019
21
Duvelisib in indolent non-Hodgkin lymphoma. ( 30799261 )
2019
22
The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells. ( 30808874 )
2019
23
7OPhase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). ( 30810203 )
2019
24
Targeting PI3K-Gamma in Non-Hodgkin Lymphoma. ( 30811291 )
2019
25
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. ( 30811293 )
2019
26
Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. ( 30815024 )
2019
27
Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. ( 30816618 )
2019
28
Single Nucleotide Polymorphisms in MIR143 Contribute to Protection Against Non-Hodgkin Lymphoma (NHL) in Caucasian Populations. ( 30818878 )
2019
29
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. ( 30820940 )
2019
30
Non-Hodgkin lymphoma in people with HIV. ( 30826280 )
2019
31
Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. ( 30826282 )
2019
32
Long-term survivors of childhood, adolescent and young adult non-Hodgkin lymphoma. ( 30714126 )
2019
33
Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives. ( 30729513 )
2019
34
Patterns of end-of-life hospital care for patients with non-Hodgkin lymphoma: exploring the landscape. ( 30732498 )
2019
35
Pediatric non-Hodgkin lymphoma: Characteristics, stratification, and treatment at a single institute in Thailand. ( 30734424 )
2019
36
Optimizing outcomes for children with non-Hodgkin lymphoma in low- and middle-income countries by early correct diagnosis, reducing toxic death and preventing abandonment. ( 30740656 )
2019
37
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. ( 30742566 )
2019
38
Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma. ( 30766960 )
2019
39
The Roles of FDG PET-CT in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy Treating Patients with Non-Hodgkin Lymphoma. ( 30769193 )
2019
40
Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes. ( 30774000 )
2019
41
The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells. ( 30782611 )
2019
42
Outcome of pediatric non-Hodgkin lymphoma in Central America: A report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA). ( 30677231 )
2019
43
Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. ( 30701541 )
2019
44
Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. ( 30702000 )
2019
45
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. ( 30709431 )
2019
46
Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma. ( 30613939 )
2019
47
Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ? ( 30617643 )
2019
48
A First in Non-Hodgkin Lymphoma Treatment. ( 30620360 )
2019
49
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. ( 30628511 )
2019
50
Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma. ( 30630175 )
2019
Sources

Variations for Lymphoma, Non-Hodgkin, Familial

About this section

UniProtKB/Swiss-Prot genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

76
# Symbol AA change Variation ID SNP ID
1 BRAF p.Gly469Ala VAR_018620 rs121913355
2 BRAF p.Gly469Arg VAR_018622 rs121913357
3 BRAF p.Asp594Gly VAR_018624 rs121913338
4 CASP10 p.Ala414Val VAR_037430 rs28936699

ClinVar genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

6 (show top 50) (show all 110)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
2 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
3 RAD54B NM_012415.3(RAD54B): c.1778A> G (p.Asn593Ser) single nucleotide variant Pathogenic rs114216685 GRCh37 Chromosome 8, 95403868: 95403868
4 RAD54B NM_012415.3(RAD54B): c.1778A> G (p.Asn593Ser) single nucleotide variant Pathogenic rs114216685 GRCh38 Chromosome 8, 94391640: 94391640
5 RAD54L NM_001142548.1(RAD54L): c.1331T> A (p.Val444Glu) single nucleotide variant Pathogenic rs121908689 GRCh37 Chromosome 1, 46738430: 46738430
6 RAD54L NM_001142548.1(RAD54L): c.1331T> A (p.Val444Glu) single nucleotide variant Pathogenic rs121908689 GRCh38 Chromosome 1, 46272758: 46272758
7 CASP10 NM_032977.3(CASP10): c.1241C> T (p.Ala414Val) single nucleotide variant Pathogenic rs28936699 GRCh37 Chromosome 2, 202074111: 202074111
8 CASP10 NM_032977.3(CASP10): c.1241C> T (p.Ala414Val) single nucleotide variant Pathogenic rs28936699 GRCh38 Chromosome 2, 201209388: 201209388
9 CASP10 NM_032977.3(CASP10): c.769C> T (p.Gln257Ter) single nucleotide variant Pathogenic rs121909775 GRCh37 Chromosome 2, 202070652: 202070652
10 CASP10 NM_032977.3(CASP10): c.769C> T (p.Gln257Ter) single nucleotide variant Pathogenic rs121909775 GRCh38 Chromosome 2, 201205929: 201205929
11 CASP10 NM_032977.3(CASP10): c.1042_1043insA (p.Gly348Glufs) insertion Pathogenic rs398122800 GRCh37 Chromosome 2, 202073912: 202073913
12 CASP10 NM_032977.3(CASP10): c.1042_1043insA (p.Gly348Glufs) insertion Pathogenic rs398122800 GRCh38 Chromosome 2, 201209189: 201209190
13 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
14 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
15 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
16 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
17 TP53 NM_000546.5(TP53): c.974G> T (p.Gly325Val) single nucleotide variant Uncertain significance rs121912659 GRCh37 Chromosome 17, 7576872: 7576872
18 TP53 NM_000546.5(TP53): c.974G> T (p.Gly325Val) single nucleotide variant Uncertain significance rs121912659 GRCh38 Chromosome 17, 7673554: 7673554
19 PRF1 NM_001083116.3(PRF1): c.1122G> A (p.Trp374Ter) single nucleotide variant Pathogenic rs104894176 GRCh37 Chromosome 10, 72358355: 72358355
20 PRF1 NM_001083116.3(PRF1): c.1122G> A (p.Trp374Ter) single nucleotide variant Pathogenic rs104894176 GRCh38 Chromosome 10, 70598599: 70598599
21 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
22 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh38 Chromosome 1, 114716124: 114716124
23 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
24 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh38 Chromosome 1, 114716123: 114716123
25 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
26 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh38 Chromosome 7, 140781603: 140781603
27 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
28 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
29 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
30 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 GRCh38 Chromosome 7, 140753354: 140753354
31 MYD88 NM_002468.5(MYD88): c.755T> C (p.Leu252Pro) single nucleotide variant Uncertain significance rs387907272 GRCh37 Chromosome 3, 38182641: 38182641
32 MYD88 NM_002468.5(MYD88): c.755T> C (p.Leu252Pro) single nucleotide variant Uncertain significance rs387907272 GRCh38 Chromosome 3, 38141150: 38141150
33 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 GRCh37 Chromosome 7, 148508727: 148508727
34 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 GRCh38 Chromosome 7, 148811635: 148811635
35 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 NCBI36 Chromosome 7, 148139660: 148139660
36 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 GRCh37 Chromosome 7, 148508728: 148508728
37 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 GRCh38 Chromosome 7, 148811636: 148811636
38 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 NCBI36 Chromosome 7, 148139661: 148139661
39 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
40 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
41 TP53 NM_000546.5(TP53): c.845G> A (p.Arg282Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs730882008 GRCh37 Chromosome 17, 7577093: 7577093
42 TP53 NM_000546.5(TP53): c.845G> A (p.Arg282Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs730882008 GRCh38 Chromosome 17, 7673775: 7673775
43 NRAS NM_002524.4(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
44 NRAS NM_002524.4(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh38 Chromosome 1, 114716123: 114716123
45 MAP2K1 NM_002755.3(MAP2K1): c.171G> C (p.Lys57Asn) single nucleotide variant Likely pathogenic rs869025608 GRCh37 Chromosome 15, 66727455: 66727455
46 MAP2K1 NM_002755.3(MAP2K1): c.171G> C (p.Lys57Asn) single nucleotide variant Likely pathogenic rs869025608 GRCh38 Chromosome 15, 66435117: 66435117
47 EZH2 NM_004456.4(EZH2): c.1936T> A (p.Tyr646Asn) single nucleotide variant Likely pathogenic rs267601395 GRCh37 Chromosome 7, 148508728: 148508728
48 EZH2 NM_004456.4(EZH2): c.1936T> A (p.Tyr646Asn) single nucleotide variant Likely pathogenic rs267601395 GRCh38 Chromosome 7, 148811636: 148811636
49 EZH2 NM_004456.4(EZH2): c.1937A> C (p.Tyr646Ser) single nucleotide variant Likely pathogenic rs267601394 GRCh37 Chromosome 7, 148508727: 148508727
50 EZH2 NM_004456.4(EZH2): c.1937A> C (p.Tyr646Ser) single nucleotide variant Likely pathogenic rs267601394 GRCh38 Chromosome 7, 148811635: 148811635

Copy number variations for Lymphoma, Non-Hodgkin, Familial from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 164351 22 36286416 36295356 Translate CEP1 Non-Hodgkin''s lymphomas
Sources

Expression for Lymphoma, Non-Hodgkin, Familial

About this section
Search GEO for disease gene expression data for Lymphoma, Non-Hodgkin, Familial.
Sources

Pathways for Lymphoma, Non-Hodgkin, Familial

About this section

Pathways related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 14.05 BCL10 BCL6 BRAF CASP10 CCND1 IRF4
2
Cytokine Signaling in Immune system 67
Show member pathways
 13.34 BCL6 BRAF CCND1 IRF4 MYC NRAS
3
IL-2 Pathway 65
Show member pathways
 13.21 BCL10 BRAF CCND1 MYC NRAS PTPRC
4
Human cytomegalovirus infection 38
Show member pathways
 12.97 CASP10 CCND1 MYC NRAS PIK3CA TP53
5
Endometrial cancer 38
Show member pathways
 12.86 BRAF CCND1 MYC NRAS PIK3CA TP53
6
Pathways in cancer 38
12.79 ALK BRAF CCND1 MYC NRAS PIK3CA
7
Gastric cancer 38
Show member pathways
 12.74 BRAF CCND1 MYC NRAS PIK3CA TP53
8
Apoptosis Modulation and Signaling 1
Show member pathways
 12.74 CASP10 IRF4 MYC NRAS PIK3CA PRF1
9
Development HGF signaling pathway 23
Show member pathways
 12.72 BRAF NPM1 NRAS PIK3CA TP53
10
Glioma 38
Show member pathways
 12.68 ALK BRAF CCND1 NRAS PIK3CA TP53
11
NF-kappaB Signaling 4
12.55 BCL10 BCL6 IRF4 PAX5 PTPRC
12
MicroRNAs in cancer 38
12.51 CCND1 MYC NRAS PIK3CA TP53
13
ErbB signaling pathway 1 38
Show member pathways
 12.51 BRAF CCND1 MYC NRAS PIK3CA TP53
14
Prolactin Signaling Pathway 1 38
Show member pathways
 12.47 CCND1 MYC NRAS PIK3CA
15
Apoptosis Pathway 73
Show member pathways
 12.44 CASP10 NRAS PIK3CA TP53
16
T cell receptor signaling pathway 38
Show member pathways
 12.42 BCL10 IRF4 NRAS PIK3CA PTPRC
17
Development IGF-1 receptor signaling 23
Show member pathways
 12.39 CCND1 MYC PIK3CA TP53
18
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.39 CCND1 MYC NRAS PIK3CA PTPRC
19
Human T-cell leukemia virus 1 infection 38
12.35 CCND1 MYC NRAS PIK3CA TP53
20
B Cell Receptor Signaling Pathway (sino) 68
Show member pathways
 12.33 BCL6 NRAS PIK3CA PTPRC
21
Viral carcinogenesis 38
12.29 CCND1 NRAS PIK3CA TP53
22
Transcriptional misregulation in cancer 38
12.26 BCL6 MYC PAX5 TP53
23
Colorectal Cancer Metastasis 65
12.18 BRAF CCND1 MYC TP53
24
mTOR Pathway 73
Show member pathways
 12.17 BRAF NRAS PIK3CA TP53
25
Cellular senescence (KEGG) 38
12.15 CCND1 MYC NRAS PIK3CA TP53
26
NGF Pathway 65
Show member pathways
 12.13 BRAF MYC NRAS TP53
27
AKT Signaling Pathway 68
12.12 CCND1 MYC NRAS PIK3CA TP53
28
Integrated Breast Cancer Pathway 1
12.12 BRAF CCND1 MYC RAD54L TP53
29
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.12 BRAF CCND1 MYC NRAS PIK3CA TP53
30
Proteoglycans in cancer 38
12.1 BRAF CCND1 MYC NRAS PIK3CA TP53
31
FoxO signaling pathway 38
Show member pathways
 12.05 BCL6 BRAF CCND1 NRAS PIK3CA
32
AGE-RAGE signaling pathway in diabetic complications 38
11.9 CCND1 NRAS PIK3CA
33
Thyroid hormone signaling pathway 38
11.9 CCND1 MYC NRAS PIK3CA TP53
34
Small cell lung cancer 38
11.86 CCND1 MYC PIK3CA TP53
35
Interleukin-4 and 13 signaling 67
11.86 BCL6 CCND1 IRF4 MYC TP53
36
Retinoblastoma (RB) in Cancer 1
11.84 CCND1 MYC TP53
37
Glioblastoma Multiforme 65
11.81 BRAF CCND1 MYC<